NorthWest Biotherapeutics Inc (NWBO)

[Bacchus1]

Bacchus1, based on your experience can you reply to a couple of questions?

1) Given the resources big pharma companies have do you see them having an advantage in the publication of important study results since they can provide the supporting studies and reply to such requests rather quickly,...? Yes, the more resources you can throw at dealing with further data/experimental requests from reviewers and Editors always helps.

2) Have you ever seen a company agree to a delay to publication because the journal offered a more prominent position in the journal, like the first or highlighted article? Not in my experience

3) When you envision the complexities of this trial (endpt and control changes, new regs to interpret, important results for the field) do you see this publication as a more challenging one to manage through the publication process? Yes I do. Anything that challenges dogma is always difficult

Thanks in advance for any perspectives.

GLTA